•  
  •  
 

Abstract

Background: Dermatophytosis is a highly prevalent superficial fungal infection in tropical regions, often chronic due to inadequate treatment. Its recurrent nature due to misuse of topical steroids and inappropriate treatment contributes significantly to both financial burden and deterioration in quality of life. This article aimed to assess the socioeconomic burden and psychological impact of dermatophytosis, accounting for its chronicity.

Methods: This study included 285 patients aged ≥12 years with previously treated dermatophytosis. Data on demographics, disease characteristics, and treatment patterns were collected. Quality of life was assessed using the Dermatology Life Quality Index (DLQI) and the Short Form-36 (SF-36) questionnaire. Socioeconomic status was classified using the Modified B. G. Prasad scale. Descriptive statistics were used for analysis.

Results: The mean age was 37.3 years, with a slight male predominance (1.08:1). Most patients belonged to lower socioeconomic strata, with an average monthly family income of 179 USD. Moderate disease involvement (3–10% body surface area) was observed in 44.9% of patients. Combined topical and systemic therapy was required in 69.1% of patients, while 35.8% reported prior use of topical steroid combinations. DLQI scores indicated a small effect in 46%, a moderate effect in 42.1%, and a very large effect in 11.9%. SF-36 findings demonstrated notable impairment in social functioning. Limitations included the absence of a detailed cost analysis and reliance on self-reported data, which is subject to recall bias.

Conclusion: Dermatophytosis impose a substantial socioeconomic burden and psychological impact on patients, necessitating the formulation of guidelines for their management.

References

  1. Rajagopalan M, Inamadar A, Mittal A, et al. Expert consensus on the management of dermatophytosis in India (ECTODERM India). BMC Dermatol. 2018;18(1):1–11.
  2. Verma SB, Panda S, Nenoff P, et al. The unprecedented epidemic-like scenario of dermatophytosis in India: I. Epidemiology, risk factors and clinical features. Indian J Dermatol Venereol Leprol. 2021;87(2):154–75.
  3. Nenoff P, Verma SB, Uhrlaß S, Burmester A, Gräser Y. A clarion call for preventing taxonomical errors of dermatophytes using the example of the novel Trichophyton mentagrophytes genotype VIII uniformly isolated in the Indian epidemic of superficial dermatophytosis. Mycoses. 2019;62(1):6–10.
  4. Das S, De A, Saha R, Sharma N, et al. The current Indian epidemic of dermatophytosis: A study on causative agents and sensitivity patterns. Indian J Dermatol. 2020;65(2):118–22.
  5. Kavita A, Thakur JS, Narang T. The burden of skin diseases in India: Global burden of disease study 2017. Indian J Dermatol Venereol Leprol. 2023;89(3):421–5.
  6. Patel NH, Padhiyar J, Patel AP, Chhebber AS, Patel BR, Patel TD. Psychosocial and financial impact of disease among patients of dermatophytosis, a questionnaire-based observational study. Indian Dermatol Online J. 2020;11(3):373–7.
  7. Kucheria M, Gupta SK, Chhina DK, et al. Clinico-mycological profile of dermatophytic infections at a tertiary care hospital in North India. Int J Com Health and Med Res. 2016;2(2):17–22.
  8. Putta SD, Kulkarni VA, Bhadade AA, Kulkarni VN, Walawalkar AS. Prevalence of dermatophytosis and its spectrum in a tertiary care hospital, Kolhapur. Indian J Basic Appl Med Res. 2016;5(3):595–600.
  9. Nivedha PA, Kaviarasan PK, Kannambal K, Poorana B, Abhirami C. Clinicoepidemiological profile of steroid-modified dermatophytosis following abuse of irrational combination of topical corticosteroid containing preparations (ICSP). IP Indian J Clin Exp Dermatol. 2020;6(4):318–24.
  10. Verma SB. Complex cost issues in treating dermatophytoses in India—“It all builds up”. Indian Dermatol Online J. 2019;10(4):441–3.
  11. Khurana A, Sardana K, Chowdhary A. Antifungal resistance in dermatophytes: Recent trends and therapeutic implications. Fungal Genet Biol. 2019;132:1–9.
  12. Golechha M. Healthcare agenda for the Indian government. Indian J Med Res. 2015;141(2):151–3.
  13. Fiammenghi E, Patalano A, Conte VL, Calabrò G. Cost analysis of inappropriate treatments for suspected dermatomycoses. Farmeconomia Health Econ Ther Pathways. 2015;16(2):39–44.
  14. Benedict K, Jackson BR, Chiller T, Beer KD. Estimation of direct healthcare costs of fungal diseases in the United States. Clin Infect Dis. 2019;68(11):1791–7.
  15. Guruprasad KY, Javed MW, Roopa C, Ansari H, Takalkar AA. Clinico-epidemiological study of dermatophytosis in a teaching hospital of North Karnataka. Int J Res Dermatol. 2019;5(1):106–9.
  16. Karki S, Pokharel DB, Parajuli S. Quality of life and economic burden in patients with dermatophytosis in a tertiary level hospital of Kathmandu, Nepal. Asian J Med Sci. 2022;13:79–83.
  17. Manickam N, Manimaran PT, Gopalan K, Somasundaram K, Vellaisamy SG. A clinico-epidemiological study to assess the impact on quality of life and financial burden in patients with dermatophytosis. J Commun Dis. 2024;56(1):36–42.
  18. Jamil RA, Saxena K, Koti VR, Mohanty S. A dermatophytosis–Its impact on quality of life and financial burden. Int J Med Biomed Stud. 2023;7(1):7–13.
  19. Shukla P, Verma P, Suvirya S, Pathania S, Kapoor D. Cutaneous dermatophytosis: A problem deeper than we perceive – a cross sectional prospective study on quality of life in 385 patients. Clin Epidemiol Glob Health. 2022;17:1–3.
  20. Rajashekar TS, Nandigonnanavar S, Kuppuswamy SK, Madhavi GS. Dermatology life quality index in patients with persisting and recurrent dermatophytoses. Int J Res Dermatol. 2019;5(1):139–43.
  21. Parmar D, Polra RV, Tandel JJ, Mauli S, Nair AP. An observational study to assess the quality of life in patients with superficial dermatophytosis at a tertiary care center. Clin Dermatol Review. 2025;9(2):128–34.
  22. Varshney AP, Gahalaut P, Pardal PK, Mishra N, Rastogi MK, Thapa M. Quality of life in patients with chronic dermatophytosis. Nepal J Dermatol Venereol Leprol. 2020;18(1):44–51.
  23. Patel NH, Padhiyar J, Gajjar T, Buch M, Tolani J. Epidemic of dermatophytosis in India: Are topical steroid adding fuel to the fire? - Hospital-based longitudinal prospective study. Sch J Appl Med Sci. 2017; 5(6):2216–223.
  24. Mohan P, Sinha S, Yadav R, Neema S, Dahiya N, Singh N. Cost-utility analysis of treating dermatophytosis: A patients’ perspective. Med J Armed Forces India. 2025;1–5.
  25. Dogra S, Uprety S. The menace of chronic and recurrent dermatophytosis in India: Is the problem deeper than we perceive? Indian Dermatol Online J. 2016;7(2):73–6

Download

Share

COinS